Novartis Expands Cancer Drug Portfolio with $3 Billion Acquisition

In a strategic move to bolster its cancer medication offerings, Novartis has entered into a definitive agreement to acquire SNV4818, a pioneering cancer drug candidate, from Synnovation Therapeutics.

The acquisition deal, worth up to $3 billion, involves a $2 billion initial payment, with an additional $1 billion contingent on development milestones.

The drug, a selective PI3Kα inhibitor, is currently being evaluated in early-stage trials, showing promise against mutated forms of the enzyme associated with breast and other solid tumors. Novartis' Chief Medical Officer, Shreeram Aradhye, emphasized the drug's potential for achieving effective cancer pathway inhibition while minimizing side effects.